Version 10.1_5 October 2020
These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website.
The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ...table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases.
Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanese
more
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more
Updated 20 Nov. 2020
Countries can use this checklist of hospital governance, structures, plans and protocols to rapidly determine the current capacities of hospitals to respond to the COVID-19 pandemic and to identify gaps and major areas that require investment and action for the development of h...ospital readiness improvement plans. The tool can be used periodically to monitor hospital emergency operational readiness capacity development
more
From Participation to Partnerships (September 2020)
Despite the COVID-19 challenges, children around the world have found meaningful ways to support and protect their peers, families, and communities. Children are on the frontlines of innovative responses and are working closely with their adult al...lies. The leadership demonstrated through these child-adult partnerships is the underlying inspiration for this guide.
more
English Analysis on World about Disaster Management and Protection and Human Rights; published on 12 Jan 2021 by IFRC
PlosOne January 20, 2021
https://doi.org/10.1371/journal.pone.0241899
Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim...icrobial resistance (AMR) and toxicity.
more
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
This publication summarizes the facilitators and barriers that will be encountered in the deinstitutionalization process and identifies useful and proven interventions in Latin American and Caribbean countries. Four areas of work are identified with the respective guidelines or suggestions for actio...n, which should provide an operational guide for countries that are restructuring mental health services and moving toward the deinstitutionalization of psychiatric care.
more
The overall goal of this strategy is to ensure accurate understanding of the
benefits of covid-19 vaccination and alleviate apprehension about the vaccine, to ensure its acceptance and encourage uptake across various audiences.
Objectives
x Create demand, promote acceptability and accessibility o...f COVID-19
vaccine among at least 90% of the general public.
x Develop appropriate messages and identify channels to communicate
the potential benefits and risks of the vaccine to all concerned parties,
including decision-makers at all levels.
x Provide timely and accurate information to address misinformation,
rumors and other crisis situations.
x Effectively mobilize and empower communities to ensure participation
and ownership of the vaccination process
x Strengthen communication mechanisms and partnerships among key
stakeholders to support the national communication effort.
more
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
The second edition of the joint WHO, WIPO and WTO
publication “Promoting Access to Medical Technologies
and Innovation: Intersections between public health,
intellectual property and trade” (the Trilateral Study),*
published in 2020, included a special insert mappi...ng the
challenges posed by the COVID-19 pandemic in relation
to the integrated health, trade and IP policy framework set
out in the study. The Trilateral Study and the special insert
were designed to serve as background reference for policy-
makers in the widest sense – lawmakers, government
officials, delegates to international organizations, non-
governmental organizations (NGOs) and researchers
who seek a comprehensive presentation of the full range
of issues, including institutions and legal concepts with
which they may be unfamiliar. It is also designed to serve
as a factual resource for the three organizations’ technical
cooperation activities.
This update revises the information contained in that
insert in the light of more recent developments as of
30 August 2021. Further updates will be made to reflect
subsequent developments.
more
This publication is a companion document to the NDVP National Deployment and Vaccination Plans guidance, which provides a framework for countries to develop their national strategies. As countries face challenges with erratic vaccine supplies, use of multiple vaccine products with different charact...eristics, and the size of populations and their diversity, this document provides operational guidance and information to support planners and immunization programme managers at the national and sub-national levels on microplanning for COVID-19 vaccination implementation.
This Guide is available in English, French, Arabic, chinese, Portuguese, Spanish, Russian
more
Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub5.
Guidance for clinical case management of thrombosis syndrome with thrombocytopenia (TTS) following vaccination to prevent coronavirus disease (COVID-19)
Interim guidance 19 July 2021
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021